---
title: "3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283044281.md"
description: "Analysts recommend three high-risk, high-reward stocks: Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMRX), all with a Strong Buy consensus and over 200% upside potential in the next year. Kura Oncology focuses on targeted cancer drugs, showing promising early data. Despite the inherent risks in drug development, analysts predict significant stock movement if clinical results are favorable, with a price target of $28.13 indicating a 218.57% upside."
datetime: "2026-04-16T19:06:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283044281.md)
  - [en](https://longbridge.com/en/news/283044281.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283044281.md)
---

# 3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026

High‑risk, high‑reward stocks appeal to investors who can handle sharp swings in price. These companies are still early in their growth journeys, but if their key catalysts play out, the returns can be explosive. According to analysts, three names worth considering now are Kura Oncology (KURA), Angel Studios (ANGX), and Immuneering (IMRX).

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

These stocks were identified using the TipRanks Stock Screener tool. All three stocks have a Strong Buy consensus rating from analysts and an upside potential of over 200% in the next 12 months.

## **1\. Kura Oncology (KURA)**

Kura Oncology is developing targeted cancer drugs for patients with specific genetic profiles. The company's lead programs focus on blocking cancer‑driving pathways found in aggressive tumors. Early data have been encouraging, and analysts think upcoming clinical results could be major catalysts for the stock.

The upside is meaningful, but risks remain. Drug development is unpredictable, and setbacks in trials or regulatory delays could hit the stock hard. Still, if Kura delivers strong data, analysts believe the shares could move sharply higher.

Turning to Wall Street, KURA stock has a Strong Buy consensus rating based on nine Buys and one Hold assigned in the last three months. At $28.13, the average Kura Oncology stock price target implies upside potential of 218.57%.

### Related Stocks

- [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)
- [ANGX.US](https://longbridge.com/en/quote/ANGX.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [BeOne Medicines: Recent FDA Approval Rewrites One-Drug Narrative](https://longbridge.com/en/news/287245995.md)
- [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)